Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review

Open Medicine

Volumn 3, Issue 2, 2009, Pages 1-20

  Molnar, Frank J ^a,b,c   Man Son Hing, Malcolm ^a,b   Hutton, Brian ^b   Fergusson, Dean A ^a,b,d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 66249137173     PISSN: None     EISSN: 19112092     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M. Global prevalence of dementia: A Delphi consensus study. Lancet. 2005;366(9503):2112-2117.
2. Wimo A, Winblad B, Stöffler A, Wirth Y, Möbius H. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics. 2003;21(5):327-340.
3. Unnebrink K, Windeler J. Intention-to-treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases. Stat Med. 2001;20(24):3931-46.
4. Engels JM, Diehr P. Imputation of missing longitudinal data: A comparison of methods. J Clin Epidemiol. 2003;56(10):968-976.
5. Gadbury GL, Coffey CS, Allison DB. Modern statistical methods for handling missing repeated measurements in obesity trial data: beyond LOCF. Obes Rev. 2003;4(3):175-184.
6. Mallinckrodt CH, Clark SWS, Carroll RJ, Molenberghs G. Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J Biopharm Stat. 2003;13(2):179-190.
7. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat. 2001;11(12): 9-21.
8. Streiner DL. Missing data and the trouble with LOCF. Evid Based Ment Health. 2008;11(1):3-5.
9. Galasko D, Edland SD, Morris JC, Clark C, Mohs R, Koss E. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years. Neurology. 1995;45(8):1451-1455.
10. Meyer K, Windler J. Intention-to-treat in progressively deteriorating diseases: Should the last observation be carried forward. J Epidemiol Biostat. 1998;3(2):199-208.
11. Mallinckrodt CH, Sanger TM, Dubé S, DeBrota DJ, Molenberghs G, Carroll RJ, et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry. 2003;53(8):754-760.
12. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998;158(9):1021-1031.
13. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000;54(3):588-593.
14. Committee For Proprietary Medicinal Products. Points to consider on missing data. London: European Agency for the Evaluation of Medicinal Products: 2001.
15. Hills R, Gray R, Stowe R. Drop-out bias undermines findings of improved functionality with cholinesterase inhibitors. Neurobiol Aging. 2002;23(Suppl 1):S89.
16. Lanctôt KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ. 2003; 169(6):557-564.
17. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289(21): 2819-2826.
18. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004;363(9427):2105-2115.
19. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin. 2005;21(8):1317-1328.
20. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: Systematic review of randomised clinical trials. BMJ. 2005;331(7512):321-327.
21. Hogan DB. Donepezil for severe Alzheimer's disease. Lancet. 2006;367(9516):1031-1032.
22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington: The Association: 1994.
24. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary. Control Clin Trials. 1996;17(1):1-12.
25. Clarke M. The QUORUM Statement. Lancet. 2000;355(9205): 756-757.
26. Rogers SL, Friedhoff LT; Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996;7(6):293-303.
27. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT; Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50(1):136-145.
28. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord. 1999;10(3):237-244.
29. Greenberg SM, Tennis MK, Brown LB, Gomez-Isla T, Hayden DL, Schoenfeld DA, et al. Donepezil therapy in clinical practice: A randomized crossover study. Arch Neurol. 2000;57(1):94-99.
30. Homma A, Takeda M, Imai Y, Udaka F, Hasegawa K, Kameyama M, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. Dement Geriatr Cogn Disord. 2000;11(6):299-313.
31. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E; Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001;57(4):613-620.
32. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57(3):481-488.
33. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc. 2001;49(12):1590-1599.
34. Thomas A, Iacono D, Bonanni L, D'Andreamatteo G, Onofrj M. Donepezil, rivastigmine, and vitamin E in Alzheimer disease: A combined P300 event-related potentials/neuropsychologic evaluation over 6 months. Clin Neuropharmacol. 2001;24(1):31-42.
35. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57(3):489-495.
36. Krishnan KRR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry. 2003;160(11):2003-2011.
37. Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: Results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry. 2003;11(2):169-177.
38. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004;63(2):214-9.
39. Moraes WdS, Poyares DR, Guilleminault C, Ramos LR, Bertolucci PHF, Tufik S. The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study. Sleep. 2006;29(2):199-205.
40. Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, et al. Efficacy of donepezil in early-stage Alzheimer disease: A randomized placebo-controlled trial. Arch Neurol. 2004;61(12):1852-1856.
41. Johannsen P, Salmon E, Hampel H, Xu Y, Richardson S, Qvitzau S, et al. Assessing therapeutic efficacy in a progressive disease: A study of donepezil in Alzheimer's disease. CNS Drugs. 2006;20(4):311-325.
42. Winblad B, Kilander L, Eriksson S, Minthon L, Båtsman S, Wetterholm A, et al. Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367(9516):1057-1065.
43. Agid Y, Dubois B, Anand R, Gharabawi G; International Rivastigmine Investigators. Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Curr Ther Res. 1998;59(12):837-845.
44. Corey-Bloom J, Anand R, Veach J; ENA 713 B352 Study. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998;1:55-65.
45. Forette F, Anand R, Gharabawi G. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur J Neurol. 1999;6(4):423-429.
46. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ. 1999;318(7184):633-638.
47. Kumar V, Anand R, Messina J, Hartman R, Veach J. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol. 2000;7(2):159-169.
48. Doraiswamy PM, Krishnan KRR, Anand R, Sohn H, Danyluk J, Hartman RD, et al. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(4):705-712.
49. Karaman Y, Erdoǧan F, Köseoǧlu E, Turan T, Ersoy ÖA. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005;19(1):51-56.
50. Raskind MA, Peskind ER, Wessel T, Yuan W; Galantamine USA-1 Study Group. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54(12):2261-2268.
51. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C; The Galantamine USA-10 Study Group. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000;54(12):2269-2276.
52. Wilcock GK, Lilienfeld S, Gaens E; Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. BMJ. 2000;321(7274):1445-1449.
53. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: A randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2001;71(5):589-595.
54. Wilkinson D, Murray J; The Galantamine Research Group. Galantamine: A randomized, doubleblind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2001;16(9):852-857.
55. Brodaty H, Corey-Bloom J, Potocnik FCV, Truyen L, Gold M, Damaraju CRV. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005;20(23): 120-132.
56. Rockwood K, Fay S, Song X, MacKnight C, Gorman M; Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) Investigators. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: A randomized controlled trial. CMAJ. 2006;174(8):1099-1105.
57. Winblad B, Poritis N. Memantine in severe dementia: Results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine. Int J Geriatr Psychiatry. 1999;14(2):135-146.
58. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ; Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14):1333-1341.
59. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317-324.
60. Pratt RD, Perdomo CA. Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Ann N Y Acad Sci. 2002;977:513-522.
61. Black S, Román GC, Geldmacher DS, Salloway S, Hecker J, Burns A, et al. Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34(10):2323-2330.
62. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, et al. Donepezil in vascular dementia: A randomised, placebo-controlled study. Neurology. 2003;61(4):479-486.
63. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet. 2002;359(9314):1283-1290.
64. Bullock R, Erkinjuntti T, Lilienfeld S; GAL-INT-6 Study Group. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-Month treatment with galantamine. Dement Geriatr Cogn Disord. 2004;17(12):29-34.
65. Orgogozo J, Rigaud A, Stöffler A, Möbius H, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33(7):1834-1839.
66. Wilcock G, Möbius HJ, Stöffler A; MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17(6):297-305.
67. Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, et al. Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial. Neurology. 2004;63(4):651-657.
68. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379-2388.
69. Koontz J, Baskys A. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: A double-blind placebo-controlled study. Am J Alzheimers Dis Other Demen. 2005;20(5):295-302.
70. Mazza M, Capuano A, Bria P, Mazza S. Ginkgo biloba and donepezil: A comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. Eur J Neurol. 2006;13(9):981-985.
71. Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007;69(5):459-469.
72. Feldman HH, Lane R; Study 304 Group. Rivastigmine: A placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2007;78(10):1056-1063.
73. Mowla A, Mosavinasab M, Haghshenas H, Haghighi AB. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol. 2007;27(5):484-487.
74. Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22(5):456-467.
75. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: Results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis. 2007;11(4):471-479.
76. Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C; GAL-INT-26 Study Group. Galantamine treatment of vascular dementia: A randomized trial. Neurology. 2007;69(5):448-458.
77. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: The InDDEx study. Lancet Neurol. 2007;6(6):501-512.
78. van Dyck CH, Tariot PN, Meyers B, Malca RE; Memantine MEM-MD-01 Study Group. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21(2):136-143.
79. Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, et al. Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006;14(8):704-715.
80. Structure and content of clinical study reports, E3; International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Geneva: The Conference: 1995.
81. Ritchie CW, Ames D, Clayton T, Lai R. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry. 2004;12(4):358-369.
82. Molnar FJ, Hutton B, Fergusson D. Does analysis using "last observation carried forward" introduce bias in dementia research. CMAJ. 2008;179(8):751-753.